Immunology Unit, Department of Cell Biology, Immunology and Neurosciences, Medical School, University of Barcelona, C/Casanova 143, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Immunol Lett. 2011 Jan 30;134(2):104-12. doi: 10.1016/j.imlet.2010.09.019. Epub 2010 Oct 7.
B cells not only play a pivotal role in humoral immunity, but also are involved in a broad spectrum of immune responses, including antigen presentation and T-cell function regulation. The identification of cell-surface CD molecules derived from a series of Human Leukocyte Differentiation Antigens (HLDA) Workshops has been instrumental to the discovery and functional characterization of human B-cell populations. Moreover, many events regulating B-cell development, activation, and effector functions are orchestrated by these cell-surface molecules. During the Ninth HLDA Workshop (HLDA9) eighteen new CDs were allocated to cell-surface molecules expressed on B cells: CD210a (IL10RA), CD215 (IL15RA), CD270 (TNFRSF14), CD307a (FCRL1), CD307b (FCRL2), CD307c (FCRL3), CD307d (FCRL4), CD351 (FCAMR), CD352 (SLAMF6), CD353 (SLAMF8), CD354 (TREM1), CD355 (CRTAM), CD357 (TNFRSF18), CD358 (TNFRSF21), CD360 (IL21RA), CD361 (EVI2B), CD362 (SDC2), and CD363 (S1PR1). Here we present their expression patterns on leukocytes, including T lymphocytes, NK cells, granulocytes, monocytes, plasmacytoid and monocyte-derived dendritic cells, and several B-cell subsets. These new CD molecules are expressed on B cells at various stages of differentiation; from bone marrow precursor pro-B cells to plasma cells. Three of them, CD307a, CD307b and CD307d, exhibit a B-cell restricted expression pattern, whereas the rest are also present on other leukocytes. In this paper we also review the structural characteristics, expression, and function of these new CD molecules. The availability of monoclonal antibodies directed against novel B cell-surface molecules will have broad implications not only for B-cell biology, but also for the development of new diagnostic and therapeutic tools.
B 细胞不仅在体液免疫中发挥关键作用，而且还参与广泛的免疫反应，包括抗原呈递和 T 细胞功能调节。从一系列人类白细胞分化抗原（HLDA）研讨会中鉴定出的细胞表面 CD 分子对于发现和功能表征人类 B 细胞群体至关重要。此外，许多调节 B 细胞发育、激活和效应功能的事件都是由这些细胞表面分子协调的。在第九届 HLDA 研讨会（HLDA9）上，十八个新的 CD 被分配给在 B 细胞上表达的细胞表面分子：CD210a（IL10RA）、CD215（IL15RA）、CD270（TNFRSF14）、CD307a（FCRL1）、CD307b（FCRL2）、CD307c（FCRL3）、CD307d（FCRL4）、CD351（FCAMR）、CD352（SLAMF6）、CD353（SLAMF8）、CD354（TREM1）、CD355（CRTAM）、CD357（TNFRSF18）、CD358（TNFRSF21）、CD360（IL21RA）、CD361（EVI2B）、CD362（SDC2）和 CD363（S1PR1）。在这里，我们展示了它们在白细胞上的表达模式，包括 T 淋巴细胞、NK 细胞、粒细胞、单核细胞、浆细胞样和单核细胞衍生的树突状细胞，以及几个 B 细胞亚群。这些新的 CD 分子在分化的各个阶段表达在 B 细胞上，从骨髓前体祖 B 细胞到浆细胞。其中三个，CD307a、CD307b 和 CD307d，表现出 B 细胞限制性表达模式，而其余的也存在于其他白细胞上。本文还回顾了这些新的 CD 分子的结构特征、表达和功能。针对新型 B 细胞表面分子的单克隆抗体的可用性不仅对 B 细胞生物学具有广泛的意义，而且对开发新的诊断和治疗工具也具有广泛的意义。
